Aqua Phase is a patented process technology, displaying a 311% increase in bioavailability of CBD in capillary blood samples compared to CBD oil. $BOD.AX expects to expand its value proposition & consolidate its position as a leading, science driven product innovator.

via Next Investors In less than two weeks $BOD.AX will know the results from the Phase IIb clinical trial using #BOD’s CBD product for insomnia sufferers. Aqua Phase has around 4 times more bioavailability than the most common delivery method for CBD. loom.ly/3UfdZDk

#ASXNews $BOD.AX Schedule 3 Clinical Trial CBD 100mg displays statistical significance over placebo with p-value of 0.04 supporting commercialization pathway whilst primary endpoint on ITT population showed no statistical significance over placebo. loom.ly/XQIWLj0 #ASX

via Next Investors $BOD.AX Phase IIb study demonstrated statistical significance in efficacy between the 100mg CBD product vs a placebo at treating insomnia. #BOD is on the cusp of becoming the first company in AUS to register a Schedule 3 CBD product. loom.ly/IuF-vlY

via Cannabiz $BOD.AX appears to have become the first company to demonstrate the efficacy of low-dose CBD for insomnia in a development which could finally see a schedule 3 product made available through pharmacies. loom.ly/Ry2Z8BM #BOD #MedicalCannabis #ASX

via Stockhead Cannabis focused biotech $BOD.AX Science surged 20% yesterday after announcing that its Schedule 3 Clinical Trial CBD 100mg displayed advantage over placebo, supporting its commercialisation plans. More: loom.ly/NokDsz0 #BOD #MedicalCannabis #ASX

via Hemp Gazette $BOD.AX has provided preliminary top-line results from its phase IIB clinical trial of a potential Schedule #3 CBD (cannabidiol) product for the local market. Read more: loom.ly/SxzvpIQ #medicalcannabis #ASX

#ASXNews $BOD.AX announces a further update on the development work to support the commercialisation of the Aqua Phase technology, with the CBD PK study investigating the bioavailability in venous blood results demonstrating 6x greater bioavailability. loom.ly/S-wHnd4

via Stockhead $BOD.AX has now completed two PK studies to demonstrate the enhanced bioavailability of #CBD when used with the Aqua Phase technology, compared with CBD in MCT oil. Read more: loom.ly/6gECZSE #BOD #ASX

via Cannabiz $BOD.AX has released further positive results from a pharmacokinetics (PK) study of its Aqua Phase technology showing six times greater bioavailability than oil-based CBD. loom.ly/FZ1ryWM #BOD #MedicalCannabis #ASX

$BOD & dsm-firmenich are proud to announce a strategic partnership. The dsm-firmenich & #BOD partnership is a significant milestone in the field of cannabinoid R&D & a step forward as companies strive to bring a #CBD product to market in the region. bit.ly/3M67D5Q #ASX

#ASXNews $BOD.AX has released its Quarterly Activities Report for the period ended 30 Sept 2023. #BOD became the only company with an advanced Schedule 3 CBD product candidate for the Australian market as well as completed its acquisition of Aqua Phase. loom.ly/fmnTyic

#ASXNews $BOD.AX presents its Annual Report for the year ended 30 June 2023. BOD agreed terms for the acquisition of Aqua Phase & completed a clinical trial assessing efficacy of a low dose soft gel CBD product in treating short-term relief of insomnia. loom.ly/qXjriAU

via Retail Pharmacy Magazine $BOD has released the results of the second pharmacokinetic study for Aqua Phase, a game-changing technology that acts as a drug delivery system to make water-hating (or lipophilic) drugs, such as cannabinoids (#CBD), water-soluble. loom.ly/1g6Vt78

Jo Patterson, CEO of $BOD, discussed with ausbiz, the innovative Aqua Phase technology, originally designed to enhance their #medicinal cannabis products but applicable across various sectors. Watch the full interview: loom.ly/J72WmLQ #BOD #ASX

#ASXNews $BOD.AX is pleased to announce that it has received firm commitments from professional and sophisticated investors for a two-tranche placement of new, fully paid ordinary shares to raise approximately $2.05 million. loom.ly/DxIdSFo #BOD #MedicalCannabis #ASX

#ASXNews $BOD.AX is pleased to release its updated Investor presentation. View the presentation here: loom.ly/rPbbTGA #BOD #BodScience #MedicalCannabis #ASX

$BOD.AX world-class “Aqua Phase" technology offers a drug delivery technology with superior bioavailability & solubility. #BOD has the optionality to commercialize valuable assets within the cannabis segment to unlock value through new products globally. loom.ly/MgpZRzU

via Stockhead CEO Jo Patterson told Stockhead that since $BOD listed on the ASX in 2016, #BOD has been focussed on & positioned downstream of the supply chain, working with exclusive cannabis extracts and drug delivery platforms. Read more: bit.ly/3G7iVDx #CBD #ASX

#ASXNews $BOD.AX has received a $1.645 million Research and Development Tax Incentive Rebate for the 2023 financial year. The funds received are reflective of #BOD's commitment and investment in R&D on key projects over the last 12 months. loom.ly/GhPOSyQ #ASX